山上 亘

Medicine & Life Sciences

1. Endometrial Neoplasms 100%
2. Japan 54%
3. Neoplasms 32%
4. Ovarian Neoplasms 30%
5. Gynecology 29%
6. Uterine Cervical Neoplasms 27%
7. Obstetrics 23%
8. Annual Reports 15%
9. Ovarian Epithelial Carcinoma 14%
10. Hereditary Nonpolyposis Colorectal Neoplasms 14%
11. Drug Therapy 14%
12. Endometrial Hyperplasia 14%
13. Therapeutics 13%
14. Neoplasm Metastasis 13%
15. DNA Mismatch Repair 12%
16. Retrospective Studies 12%
17. Registries 11%
18. Carcinoma 11%
19. Carboplatin 11%
20. Survival 10%
21. Paclitaxel 10%
22. Guidelines 10%
23. Fertility 9%
24. Medroxyprogesterone Acetate 9%
25. Adenomyoma 9%
26. Endometrioid Carcinoma 9%
27. Lymph Nodes 9%
28. Irinotecan 8%
29. Radiotherapy 8%
30. Hysteroscopy 8%
31. Genes 8%
32. Granulosa Cell Tumor 8%
33. Lymph Node Excision 8%
34. Adenocarcinoma 7%
35. Vulvar Neoplasms 7%
36. Sentinel Lymph Node 7%
37. Hypertriglyceridemia 6%
38. Survival Rate 6%
39. Recurrence 6%
40. Microsatellite Instability 6%
41. Bevacizumab 6%
42. Chemoradiotherapy 6%
43. Cancer Survivors 6%
44. Salpingo-oophorectomy 6%
45. MicroRNAs 6%
46. Epigenomics 6%
47. Carcinogenesis 5%
48. Regulatory T-Lymphocytes 5%
49. Platinum 5%